NICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...
Read moreCanadians pay too much for prescription drugs – and that means far too many go without the medicin...
Read moreFollowing a series of FOI requests to CCGs, MTG said a number of CCGs are currently restricting acce...
Read moreInitially NICE rejected Illumetri for not being cost-effective, but a new negotiated price means th...
Read moreSpeaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...
Read moreAdults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scot...
Read moreRoche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in ...
Read moreA new game changing treatment for people with multiple myeloma will now be available on the NHS in E...
Read moreThe only CAR-T cell therapy available for NHS patients in England and Wales for two distinct blood c...
Read morePfizer has announced that it plans to increase the list price of 41 medicines, or 10% of its entire ...
Read more